Rapid human immunodeficiency virus-1 testing on labor and delivery in 17 US hospitals: the MIRIAD experience - 21/08/11
, Mardge H. Cohen, MD 3, Robert Maupin, MD 4, Steven Nesheim, MD 5, Susan P. Danner, BA 1, Margaret A. Lampe, RN, MPH 1, Mary Jo O’Sullivan, MD 6, Mayris P. Webber, DrPH 7, Jeffrey Wiener, MS 1, 2, Rosalind J. Carter, PhD 7, 8, Yvette Rivero, BA 6, Mary Glenn Fowler, MD, MPH 1, 9, Marc Bulterys, MD, PhD 1, 10
Reprints: Denise J. Jamieson, MD, MPH, Centers for Disease Control and Prevention, 4770 Buford Hwy, Mailstop K-34, Atlanta, GA 30341Résumé |
The objective of the study was to evaluate the feasibility, acceptability, and accuracy of rapid human immunodeficiency virus (HIV) testing during labor. The Mother-Infant Rapid Intervention at Delivery (MIRIAD) study was a prospective, multicenter study that offered voluntary, rapid HIV testing to women with undocumented HIV status at 17 hospitals in 6 cities. Of 12,481 eligible women, 74% were approached for participation and 85.5% of those approached accepted rapid HIV testing. Among 7753 women tested, MIRIAD identified 52 (0.7%) HIV-infected women. The time between obtaining the blood sample for the rapid test and reporting the results to the health care provider was shorter for hospitals utilizing point-of-care testing than in hospitals utilizing laboratory-based testing (30 minutes vs 68 minutes; P < .0001), and point-of-care testing strategies were 14 times more likely to have a short turnaround as laboratory testing strategies. Routine rapid testing during labor provides a feasible, acceptable, and accurate way to identify HIV-infected women before delivery.
Le texte complet de cet article est disponible en PDF.Key words : rapid human immunodeficiency virus testing
Plan
| This research was supported by the National Center for HIV, STD, and TB Prevention, Centers for Disease Control and Prevention, under cooperative agreements U64/217724, 417719, 517715, 617734, and 479935. |
|
| The views expressed herein are those of the authors and do not necessarily represent the views of the Centers for Disease Control and Prevention. Use of trade names is for identification purposes only and does not constitute endorsement by the Centers for Disease Control and Prevention or the Department of Health and Human Services. |
Vol 197 - N° 3S
P. S72-S82 - septembre 2007 Retour au numéro
Article précédent
- Infant human immunodeficiency virus diagnosis in resource-limited settings: issues, technologies, and country experiences
- Tracy L. Creek, Gayle G. Sherman, John Nkengasong, Lydia Lu, Thomas Finkbeiner, Mary Glenn Fowler, Emilia Rivadeneira, Nathan Shaffer
- Approaches for scaling up human immunodeficiency virus testing and counseling in prevention of mother-to-child human immunodeficiency virus transmission settings in resource-limited countries
- Omotayo O. Bolu, Virginia Allread, Tracy Creek, Elizabeth Stringer, Fatu Forna, Marc Bulterys, Nathan Shaffer
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?